Loading
A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07213609 by GlaxoSmithKline, with 47 participants planned, started 2025-10-20 and due to reach its primary completion in 2028-09-28. Interventions recorded: GSK5460025.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/